Pramlintide

Symlin

Pramlintide replicates the physiological role of amylin, which is deficient in type 1 diabetes and progressively lost in type 2 diabetes as beta-cell function declines. Structurally, it differs from native human amylin by three proline substitutions at positions 25, 28, and 29, which prevent the amyloid aggregation that makes native amylin unsuitable for pharmaceutical use. The molecule activates amylin receptors — complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMP1, RAMP2, or RAMP3) — in the area postrema and hypothalamus, driving three complementary effects: suppression of inappropriate postprandial glucagon secretion, deceleration of gastric emptying to blunt glucose excursions, and central satiety signaling that reduces caloric intake. In clinical trials, pramlintide added to optimized insulin therapy reduced HbA1c by approximately 0.3–0.6% with concomitant weight loss of 1–2 kg over 12 months — a notable contrast to the weight gain typically associated with insulin intensification. The drug received FDA approval in 2005 for use as adjunctive therapy in type 1 and type 2 diabetes patients who have not achieved adequate glycemic control on mealtime insulin. Its primary safety concern is insulin-mediated hypoglycemia, which requires a 50% reduction in prandial insulin dose at initiation. Pramlintide has also attracted research interest in the obesity space, both as monotherapy and in combination with metreleptin (leptin analog), where the dual amylin-leptin axis produced approximately 12% weight loss in early trials — results that informed the development of next-generation amylin analogs like cagrilintide.